CAMBRIDGE, Mass., June 14, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) (“Aegerion”), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, today announced the pricing of an underwritten public offering of 3,400,000 shares of common stock at a price to the public of $14.75 per share. The net proceeds to Aegerion from this offering are expected to be approximately $47.3 million, after deducting underwriting discounts and commissions. The offering is expected to close on June 19, 2012, subject to customary closing conditions.
